PL3801490T3 - Związki do zastosowania w kacheksji nowotworowej - Google Patents

Związki do zastosowania w kacheksji nowotworowej

Info

Publication number
PL3801490T3
PL3801490T3 PL19730484.3T PL19730484T PL3801490T3 PL 3801490 T3 PL3801490 T3 PL 3801490T3 PL 19730484 T PL19730484 T PL 19730484T PL 3801490 T3 PL3801490 T3 PL 3801490T3
Authority
PL
Poland
Prior art keywords
compounds
cancer cachexia
cachexia
cancer
Prior art date
Application number
PL19730484.3T
Other languages
English (en)
Inventor
Kieran Clarke
Peter HESPEL
Original Assignee
Tdeltas Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tdeltas Limited filed Critical Tdeltas Limited
Publication of PL3801490T3 publication Critical patent/PL3801490T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Pediatric Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19730484.3T 2018-06-04 2019-06-03 Związki do zastosowania w kacheksji nowotworowej PL3801490T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1809113.2A GB2575623B (en) 2018-06-04 2018-06-04 3-hydroxybutyrate esters for treating cancer cachexia
PCT/GB2019/051532 WO2019234402A1 (en) 2018-06-04 2019-06-03 Compounds for use in cancer cachexia

Publications (1)

Publication Number Publication Date
PL3801490T3 true PL3801490T3 (pl) 2025-04-14

Family

ID=62872859

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19730484.3T PL3801490T3 (pl) 2018-06-04 2019-06-03 Związki do zastosowania w kacheksji nowotworowej

Country Status (11)

Country Link
US (1) US12226387B2 (pl)
EP (1) EP3801490B1 (pl)
JP (1) JP7402826B2 (pl)
KR (1) KR102863322B1 (pl)
CN (1) CN112384211B (pl)
CA (1) CA3102503A1 (pl)
DK (1) DK3801490T3 (pl)
ES (1) ES3014285T3 (pl)
GB (1) GB2575623B (pl)
PL (1) PL3801490T3 (pl)
WO (1) WO2019234402A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021195477A1 (en) * 2020-03-27 2021-09-30 Ketoneaid, Inc. Ketone ester as a therapeutic treatment of covid-19, long covid, and related viral infections
AU2022387742A1 (en) * 2021-11-12 2024-06-27 Arxada Ag Polyol-derived compounds
JP2024080456A (ja) * 2022-12-02 2024-06-13 国立大学法人広島大学 筋量維持剤およびその用途
KR102964048B1 (ko) 2024-03-28 2026-05-11 한림대학교 산학협력단 암 악액질의 예방 또는 치료를 위한 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1648952T3 (en) * 2003-06-03 2018-05-28 The Us Gov As Represented By The Department Of Health And Human Services Dietary supplements and therapeutic compositions comprising (R) -3-hydroxybutyrate derivatives
EP2738792B1 (en) 2003-06-13 2015-08-05 Nikon Corporation Exposure method, substrate stage, exposure apparatus, and device manufacturing method
US8642654B2 (en) * 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
ES2655367T3 (es) * 2008-08-21 2018-02-19 Oxford University Innovation Limited Bebida que comprende éster de hidroxibutirato y uso médico de la misma
GB201002983D0 (en) * 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
JP2011192991A (ja) 2010-03-12 2011-09-29 Asml Netherlands Bv リソグラフィ装置および方法
GB201206192D0 (en) * 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output
EP2925308B1 (en) 2012-11-28 2019-12-25 University Of South Florida Targeting cancer with metabolic therapy and hyperbaric oxygen
GB201304467D0 (en) * 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
GB2515603B (en) 2013-03-14 2015-10-14 Isis Innovation Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate
GB201314127D0 (en) * 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
WO2018114309A1 (en) * 2016-12-23 2018-06-28 Katholieke Universiteit Leuven 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment

Also Published As

Publication number Publication date
GB2575623A (en) 2020-01-22
US20210212977A1 (en) 2021-07-15
EP3801490B1 (en) 2024-12-04
GB201809113D0 (en) 2018-07-18
KR20210019052A (ko) 2021-02-19
JP7402826B2 (ja) 2023-12-21
DK3801490T3 (da) 2025-03-03
GB2575623B (en) 2022-10-26
KR102863322B1 (ko) 2025-09-22
CN112384211A (zh) 2021-02-19
EP3801490A1 (en) 2021-04-14
JP2021525775A (ja) 2021-09-27
US12226387B2 (en) 2025-02-18
CN112384211B (zh) 2025-01-03
WO2019234402A1 (en) 2019-12-12
ES3014285T3 (en) 2025-04-21
CA3102503A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
SG11202104356VA (en) Bt1718 for use in treating cancer
IL266012A (en) Combination therapy for c3 inhibition
IL254705B (en) Combined treatment for cancer
LT3806898T (lt) Gremlin-1 antagonistas, skirtas naudoti vėžio gydymui
ZA201804968B (en) Formulations for treating bladder cancer
PT3988541T (pt) Compostos heterocíclicos para visualização e tratamento de cancro e métodos para o seu uso
ZA202005847B (en) Cancer therapy
IL282093B1 (en) Combination therapy for cancer
ZA202006988B (en) Composition for supporting animal with cancer
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
SI3534885T1 (sl) Zaviralci farnezil-transferaze za uporabo pri zdravljenju raka
EP3736275C0 (en) PRODRUGS OF OXABICYCLOHEPTANE FOR USE IN THE TREATMENT OF CANCER
GB201702160D0 (en) Inhibitors for use in therapy
SG11201803551YA (en) Melflufen dosage regimens for cancer
PL3389717T3 (pl) Terapia neoadjuwantowa raka pęcherza moczowego
GB201800733D0 (en) Cancer
DK3801490T3 (da) Forbindelser til anvendelse i cancerkakeksi
SG11202010528XA (en) Combinations for treating cancer
GB201701400D0 (en) Compound for use in medicine
GB201814487D0 (en) Cancer
IL283687A (en) usp19 inhibitors and their use for therapeutic purposes
GB201913957D0 (en) Cancer
IL269121A (en) Usl-311 for use in the treatment of cancer
IL287508B2 (en) Indole compounds for use in neural rehabilitation
GB2571849B (en) Treatments for cachexia